IndustryCompany release

MaxCyte lifts 2026 revenue guidance and proposes Akron Bio acquisition after 49% third-quarter growth

🇺🇸 Maxcyte, Inc. (MXCT) · Tue 10 Nov 2026

The cell-engineering company reported $10.2 million in third-quarter revenue and plans to buy a GMP-grade reagent supplier, partly funded by a $22 million credit facility draw.

MaxCyte, a US cell-engineering platform company, reported third-quarter 2026 results on 10 November, with total revenue of $10.2 million. The company's headline described this as a 49% increase on the prior-year period. Core revenue was $8.2 million, while revenue linked to its SPL programme-related business contributed $2.0 million.

The company recorded a net loss of $4.8 million for the quarter. Cash and investments stood at $132.7 million at 30 September.

MaxCyte raised its full-year revenue guidance to at least $34.5 million. The summary available does not give the previous guidance range, nor a breakdown of the revised outlook.

The company also announced a proposed acquisition of Akron Bio, a supplier of GMP-grade reagents used in cell therapy manufacturing. MaxCyte plans to fund part of the deal with a $22 million draw on its MidCap Financial credit facility. Purchase price, expected closing date and conditions were not available in the material reviewed, and the deal is described as proposed rather than completed.

What it means for your team

  • Quality teams at cell therapy developers may want to watch how the proposed deal affects reagent supply arrangements, since GMP-grade materials are a critical input to manufacturing.
  • Any change of ownership at a reagent supplier could prompt supplier qualification or change-control reviews, though no such changes have been announced.
  • Market-access and business-development teams can read the raised guidance and the move into reagents as signs of MaxCyte widening its role in the cell therapy supply chain.
  • Deal terms and timing remain undisclosed in the available material, so downstream effects are not yet assessable.

Company's press release (SEC filing): Maxcyte, Inc. ↗

Article written by VigiEye from the official source (Maxcyte, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →